Results 171 to 180 of about 6,798 (212)
Some of the next articles are maybe not open access.

Immunotoxins

Annual Review of Immunology, 1985
E S, Vitetta, J W, Uhr
  +5 more sources

Immunotoxins: the power and the glory

Immunology Today, 1992
Immunotoxins are hybrid proteins in which the potent cytocidal action of a toxin is harnessed for the selective destruction of target cells by attachment to a specific monoclonal antibody (mAb) or growth factor. This brief article describes the latest advances in the molecular and cellular biology, pharmacology and clinical evaluation of immunotoxins ...
E J, Wawrzynczak, E J, Derbyshire
openaire   +2 more sources

Immunotoxins and Recombinant Immunotoxins in Cancer Therapy

2006
Targeted cancer therapy in general and immunotherapy in particular, combines rational drug design with the progress in understanding cancer biology. This approach takes advantage of our recent knowledge of the mechanisms by which normal cells are transformed into cancer cells, thus, using the special properties of cancer cells to device novel ...
Yoram Reiter, Avital Lev
openaire   +1 more source

Immunotoxins

Cell, 1986
I, Pastan   +2 more
openaire   +2 more sources

Immunotoxins

Scientific American, 1984
R J, Collier, D A, Kaplan
openaire   +2 more sources

Immunotoxins in cancer therapy

Current Opinion in Immunology, 1999
Immunotoxins are composed of a protein toxin connected to a binding ligand such as an antibody or growth factor. These molecules bind to surface antigens (which internalize) and kill cells by catalytic inhibition of protein synthesis within the cell cytosol.
openaire   +2 more sources

[Immunotoxins].

Bulletin du cancer, 1983
Immunotoxins are conjugates between antibodies especially directed against cancer cells and a subunit of a powerful toxin. We used the A-chain of ricin. These conjugates are specifically cytotoxic when used at very low concentrations in vitro and can destroy more than 99.99% of clonogenic cells.
F K, Jansen   +13 more
openaire   +1 more source

ImmunoPeCa Trial: Long-Term Outcome Following Intraperitoneal MOC31PE Immunotoxin Treatment in Colorectal Peritoneal Metastasis

European Journal of Surgical Oncology, 2021
Kjersti Flatmark   +2 more
exaly  

Immunotoxins

2009
Arthur E. Frankel   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy